204 related articles for article (PubMed ID: 28962634)
21. Parkinson's disease: trials and travesties.
Morrish P
Pract Neurol; 2007 Apr; 7(2):132. PubMed ID: 17430881
[No Abstract] [Full Text] [Related]
22. Potential subjects' responses to an ethics questionnaire in a phase I study of deep brain stimulation in early Parkinson's disease.
Finder SG; Bliton MJ; Gill CE; Davis TL; Konrad PE; Charles PD
J Clin Ethics; 2012; 23(3):207-16. PubMed ID: 23256400
[TBL] [Abstract][Full Text] [Related]
23. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
24. Abnormal Olfaction in Parkinson's Disease Is Related to Faster Disease Progression.
Cavaco S; Gonçalves A; Mendes A; Vila-Chã N; Moreira I; Fernandes J; Damásio J; Teixeira-Pinto A; Bastos Lima A
Behav Neurol; 2015; 2015():976589. PubMed ID: 26136625
[TBL] [Abstract][Full Text] [Related]
25. Impact of placebo assignment in clinical trials of Parkinson's disease.
Goetz CG; Janko K; Blasucci L; Jaglin JA
Mov Disord; 2003 Oct; 18(10):1146-9. PubMed ID: 14534918
[TBL] [Abstract][Full Text] [Related]
26. Knowledge of and attitudes toward clinical trials in Saudi Arabia: a cross-sectional study.
Al-Rawashdeh N; Damsees R; Al-Jeraisy M; Al Qasim E; Deeb AM
BMJ Open; 2019 Oct; 9(10):e031305. PubMed ID: 31641002
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study.
Amboni M; Stocchi F; Abbruzzese G; Morgante L; Onofrj M; Ruggieri S; Tinazzi M; Zappia M; Attar M; Colombo D; Simoni L; Ori A; Barone P; Antonini A;
Parkinsonism Relat Disord; 2015 Jun; 21(6):644-9. PubMed ID: 25899545
[TBL] [Abstract][Full Text] [Related]
28. The 39 item Parkinson's disease questionnaire (PDQ-39) revisited: implications for evidence based medicine.
Hagell P; Nygren C
J Neurol Neurosurg Psychiatry; 2007 Nov; 78(11):1191-8. PubMed ID: 17442762
[TBL] [Abstract][Full Text] [Related]
29. Sex and cardiovascular disease status differences in attitudes and willingness to participate in clinical research studies/clinical trials.
Gruca TS; Hottel WJ; Comstock J; Olson A; Rosenthal GE
Trials; 2018 May; 19(1):300. PubMed ID: 29843818
[TBL] [Abstract][Full Text] [Related]
30. Pharmacotherapy of Parkinson's disease in Germany.
Möller JC; Körner Y; Dodel RC; Meindorfner C; Stiasny-Kolster K; Spottke A; Krüger HP; Oertel WH
J Neurol; 2005 Aug; 252(8):926-35. PubMed ID: 15765268
[TBL] [Abstract][Full Text] [Related]
31. Validation of the "QUICK" questionnaire--a tool for diagnosis of "wearing-off" in patients with Parkinson's disease.
Martinez-Martin P; Tolosa E; Hernandez B; Badia X;
Mov Disord; 2008 Apr; 23(6):830-6. PubMed ID: 18307246
[TBL] [Abstract][Full Text] [Related]
32. Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret.
Stryker JE; Wray RJ; Emmons KM; Winer E; Demetri G
Patient Educ Couns; 2006 Oct; 63(1-2):104-9. PubMed ID: 16242898
[TBL] [Abstract][Full Text] [Related]
33. Dietary habits and neurological features of Parkinson's disease patients: Implications for practice.
Barichella M; Cereda E; Cassani E; Pinelli G; Iorio L; Ferri V; Privitera G; Pasqua M; Valentino A; Monajemi F; Caronni S; Lignola C; Pusani C; Bolliri C; Faierman SA; Lubisco A; Frazzitta G; Petroni ML; Pezzoli G
Clin Nutr; 2017 Aug; 36(4):1054-1061. PubMed ID: 27406858
[TBL] [Abstract][Full Text] [Related]
34. Impact of the Parkinson's disease medication protocol program on nurses' knowledge and management of Parkinson's disease medicines in acute and aged care settings.
Chenoweth L; Sheriff J; McAnally L; Tait F
Nurse Educ Today; 2013 May; 33(5):458-64. PubMed ID: 22626862
[TBL] [Abstract][Full Text] [Related]
35. Parkinson's disease. Update in diagnosis and symptom management.
Marjama-Lyons JM; Koller WC
Geriatrics; 2001 Aug; 56(8):24-5, 29-30, 33-5. PubMed ID: 11505857
[TBL] [Abstract][Full Text] [Related]
36. Predictors of the placebo response in clinical trials on Parkinson's disease: A meta-analysis.
Shin CW; Hahn S; Park BJ; Kim JM; Park EO; Jeon B
Parkinsonism Relat Disord; 2016 Aug; 29():83-9. PubMed ID: 27237106
[TBL] [Abstract][Full Text] [Related]
37. Mirror movements in Parkinson's disease: An under-appreciated clinical sign.
Chatterjee P; Banerjee R; Choudhury S; Mondal B; Kulsum MU; Chatterjee K; Kumar H
J Neurol Sci; 2016 Jul; 366():171-176. PubMed ID: 27288800
[TBL] [Abstract][Full Text] [Related]
38. Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease.
Martinez-Martin P; Rodriguez-Blazquez C; Forjaz MJ; Kurtis MM
CNS Drugs; 2015 May; 29(5):397-413. PubMed ID: 25968563
[TBL] [Abstract][Full Text] [Related]
39. Rising to the Challenges of Clinical Trial Improvement in Parkinson's Disease.
Mathur S; DeWitte S; Robledo I; Isaacs T; Stamford J
J Parkinsons Dis; 2015; 5(2):263-8. PubMed ID: 25720445
[TBL] [Abstract][Full Text] [Related]
40. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience.
Elm JJ; Kamp C; Tilley BC; Guimaraes P; Fraser D; Deppen P; Brocht A; Weaver C; Bennett S;
Mov Disord; 2007 Apr; 22(6):822-7. PubMed ID: 17357141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
